FRANKFURT (Reuters) - Bayer said it halted trials testing its experimental uterine fibroids treatment vilaprisan, which it previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.
Frankfurt, Germany-based Bayer reported that it had halted enrollment in a clinical trial of its vilaprisan for uterine fibroids.